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There is some evidence that the histaminergic neuron system is implicated in the 
pathophysiology of schizophrenia1, 2).  Indeed, a significant increase in the level of Nτ
-methylhistamine was found in the cerebrospinal fluid of schizophrenics when compared to 
controls3).  In addition, in postmortem binding studies using 3H-mepyramine as a ligand, 
Nakai et al. found that the number of histamine H1 receptors in the frontal cortex of 
schizophrenics was reduced4).  Although previous findings have suggested that the high 
activity of brain histamine synthesis or release could be related to schizophrenia, no report 
has investigated the measurement of brain H1 receptors in schizophrenic patients in vivo.   
In this study, the distribution of histamine H1 receptors in schizophrenics was 
compared to that in normal subjects.  We measured cerebral H1 receptor binding by PET 
and [11C] doxepin in 10 patients with schizophrenia and in age-matched 10 normal subjects 
using the same methods used in the studies of H1 receptor occupancy.   
 
Methods 
Ten male patients with schizophrenia and ten normal male volunteers with no 
neurological abnormalities were enrolled in this study.  The schizophrenic subjects were 
diagnosed according to the diagnostic and statistical manual of mental disorders (DSM)-IV 
criteria from the clinical services affiliated with Tohoku University Hospital.  
Psychopathology was assessed by means of brief psychiatric rating scale (BPRS) as shown 
in Table 1.  Healthy control subjects were recruited through advertisement.  Based on 
unstructured psychiatric screening interviews, the control subjects were free of and never 
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had any psychiatric or major medical diseases, had no relatives with neuropsychiatric 
disorders, and showed no anatomical abnormalities according to MRI images.  All 
schizophrenic patients were treated with haloperidol.  Nine patients were treated for 
akathisia with biperiden, and five patients were treated for insomnia or anxiety with 
benzodiazepines [flunitrazepam (2 patients), brotizolam, cloxazolam, and quazepam (1 
patient each)].   
PET measurements were performed at Tohoku University Cyclotron Radioisotope 
Center using SET2400W scanner in three-dimensional mode.  Binding potential (BP = 
Bmax / Kd) values of [11C] doxepin for available brain histamine H1-receptors in the 
schizophrenics and control subjects were calculated using a previously-reported method of 
H1 receptor occupancy5-7).   
 
Results 
Averaged PET images obtained 45-90 min after intravenous injection of [11C] 
doxepin are shown in Fig. 1.  High radioactivity was observed in the frontal, temporal and 
occipital cortices, the cingulate gyrus, striatum and thalamus in the normal subjects.  On 
the other hand, the distribution patterns of radioactivity in the cortical areas of 
schizophrenic patients were apparently lower than those of the control subjects.   
Parametric neuroimages of BP of [11C] doxepin in the schizophrenic patients and in 
the control subjects were constructed by graphical analysis and statistically compared using 
SPM99 on a voxel-by-voxel basis (Fig. 2) (Table 2).  The colored areas show areas where 
BP values in the schizophrenic patients were significantly lower than those in the control 
subjects.  In addition, histamine H1 receptors density was significantly low in the cortices, 
especially the frontal and prefrontal, and the cingulate gyrus, which are known to be 
H1-receptor rich regions.  In contrast, SPM99 analysis could not detect any area where BP 
values were significantly higher in the schizophrenic patients than in the control subjects.  
BP values in the prefrontal cortex, anterior cingulate cortex, posterior cingulate 
cortex, and thalamus were evaluated using ROI-based analysis (Fig. 3).  BP values in the 
schizophrenic patients were significantly lower than those in the controls in the prefrontal 
cortex and cingulated cortex.   
 
Discussion 
H1 receptors estimated on a voxel-by-voxel basis using SPM99 were significantly 
lower in several brain areas of the schizophrenic patients than in the normal subjects.  
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Similarly, H1 receptor bindings evaluated using ROIs placed on the prefrontal cortex and 
the anterior and posterior cingulate gyrus were significantly lower in the schizophrenic 
patients than in the normal subjects.  These results are generally consistent with those of 
histamine H1 receptor binding assays in post-mortem schizophrenic patients brain
4).  The 
present study demonstrates for the first time the decrease of histamine H1 receptor density 
in the brain of schizophrenic patients in vivo by PET, though a careful interpretation of our 
results is needed. 
The PET findings of this study are preliminary and require replication because of 
the relatively small number of subjects and the problem of patients medication.  However, 
the present study clealy demonstrates a decrease of histamine H1 receptors in chronic 
schizophrenics by PET.  It is speculated that neuronal histamine functions as a 
bio-protective system against various noxious and unfavorable stimuli such as convulsion, 
nociception, drug sensitization, ischemic lesions, and stress8).  There is evidence that 
implicates brain histamine in animal model of psychosis9, 10).  The decrease of H1 receptors 
observed in the schizophrenic patients in this study would be a consequence of 
downregulation caused by excessive histamine release from histamine neurons.  Here we 
propose that histamine neurons have an inhibitory role on the development of 
stress-vulnerability or schizophrenic symptoms.  To confirm this, further studies, 
particularly studies of drug-naïve patients, are needed.   
Recently, Pillot et al. reported that acute administration of ciproxifan, a histamine H3 
receptor antagonist/inverse agonist, potentiates the neurochemical and behavioral effects of 
haloperidol in the rat11).  These results suggest that histaminergic neurotransmission may 
be involved in the pathophysiology of schizophrenia and that dysfunction of the 
histaminergic neuron system might be important as one of the extra-dopaminergic 
functional abnormalities in the schizophrenic brain.  Therefore, activation of the 





 1)  Usdin E., Hamburg D.A., Barchas J.D. et al., Stripling JS. Proceedings of a conference on  
neuroregulators and hypotheses of psychiatric disorders held at the asilomar conference center,  
pacific grove, california, january 13-16, 1976. New York: Oxford University Press, 1977. 
 2)  Rauscher F.P., Nasrallah H.A., Wyatt R.J. et al., J. Clin. Psychiatry 41 (1980) 44. 
 3)  Prell G.D., Green J.P. and Kaufmann C.A., Schizophr. Res. 14 (1995) 93. 
 4)  Nakai T., Kitamura N., Hashimoto T. et al., Biol. Psychiatry 30 (1991) 349. 
 5)  Logan J., Fowler J.S., Volkow N.D. et al., J. Cereb. Blood. Flow. Metab. 110 (990) 740. 
 6)  Okamura N., Yanai K., Higuchi M. et al., Br. J. Pharmacol. 129 (2000) 115. 
 7)  Tagawa M., Kano M., Okamura N. et al., Br. J. Clin. Pharmacol. 52 (2001) 501. 
 195
 8)  Watanabe T. and Yanai K., Tohoku J. Exp. Med. 195 (2001) 197. 
 9)  Ito C., Sato M., Onodera K. et al., Ann. N. Y. Acad. Sci. 801 (1996) 353. 
10)  Morisset S., Pilon C., Tardivel-Lacombe J. et al., J. Pharmacol. Exp. Ther. 300 (2002) 621. 
11)  Pillot C., Ortiz J., Heron A. et al., J. Neurosci. 22 (2002) 7272. 
 
 
Table 1.  Clinical features of the ten schizophrenic patients.  Age at PET scan, morbidity periods, daily dose 












1 38 16y 1.5mg 1mg Brotizolam0.25mg 10 
2 21 2y 3mg 2mg  15 
3 29 3.5y 1.5mg 1mg  20 
4 30 3y 6mg 2mg Cloxazolam 2mg 24 
5 36 10y 5mg 8mg  11 
6 26 9y 15mg 4mg  26 
7 31 1y 9mg 3mg Quazepam 15mg 27 
8 29 12y 4.5mg 3mg Flunitrazepam 2mg 14 
9 36 19y 2.5mg   29 
10 20 2.5y 9mg 6mg Flunitrazepam 1mg 17 
 
 
Table 2.  Regional maxima showing significant differences in BP values estimated by SPM99 between 
schizophrenic patients and the controls (p<0.001, uncorrected).   
Talairach coordinates 
   Area       (Brodmann area) Side Z-score 
x y z 
Gyrus frontalis medialis (8) L 4.37 -10 32 44 
Gyrus frontalis inferior (47) L 4.33 -28 30 -12 
Gyrus frontalis medius (9) L 4.05 -28 42 36 
Gyrus frontalis medius (6) L 3.95 -46 4 46 
Gyrus frontalis inferior (47) R 3.87 46 26 -2 
Gyrus occipitalis medius (19) L 3.69 -50 -60 -4 
Gyrus lingualis (18) R 3.54 16 -82 0 
Precuneus (7) R 3.53 16 -34 50 
Gyrus frontalis medialis (6) L 3.46 -12 -8 48 







Fig. 1.  Brain distribution of [11C]-doxepin radioactivity in schizophrenic patients and healthy control 
subjects.  Averaged PET images are shown at the corresponding levels.  The images were obtained 45-90 





Fig. 2.  Brain distribution of [11C]-doxepin radioactivity in schizophrenic patients and healthy control 
subjects using SPM99.  The colored areas show areas where BP values of [11C]-doxepin in schizophrenic 
patients were significantly lower than those in the control subjects (p<0.001, uncorrected). 
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Fig. 3.  ROI-based analysis of histamine H1 receptors in the prefrontal cortex, anterior cingulated cortex, 
posterior cingulated cortex and thalamus.  BP values (means+/-SD) for the schizophrenic patients (■) and 
the controls (□) are shown.  *p<0.05 Statistically analyzed by non paired t-test.   
 
 
 
 
